Siguazodan is primarily used in research settings to study its effects on phosphodiesterase III (PDE III) inhibition. It has been investigated for its potential therapeutic applications in cardiovascular diseases, particularly in heart failure. The compound has shown promise in enhancing cardiac contractility and vasodilation, which can improve blood flow and overall heart function. Additionally, Siguazodan has been explored for its potential anti-inflammatory properties, making it a subject of interest in conditions where inflammation plays a key role. Its applications are largely confined to preclinical studies, aiming to better understand its mechanisms and potential benefits in various medical contexts.